These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27197305)

  • 1. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
    Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
    Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma.
    Moore SJ; Hayden Gephart MG; Bergen JM; Su YS; Rayburn H; Scott MP; Cochran JR
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14598-603. PubMed ID: 23950221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chemically cross-linked knottin dimer binds integrins with picomolar affinity and inhibits tumor cell migration and proliferation.
    Kim JW; Cochran FV; Cochran JR
    J Am Chem Soc; 2015 Jan; 137(1):6-9. PubMed ID: 25486381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
    D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
    Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
    Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
    Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides.
    Willmann JK; Kimura RH; Deshpande N; Lutz AM; Cochran JR; Gambhir SS
    J Nucl Med; 2010 Mar; 51(3):433-40. PubMed ID: 20150258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
    Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
    Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.
    Gong X; Azhdarinia A; Ghosh SC; Xiong W; An Z; Liu Q; Carmon KS
    Mol Cancer Ther; 2016 Jul; 15(7):1580-90. PubMed ID: 27207778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
    Burns KE; Hensley H; Robinson MK; Thévenin D
    Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
    Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
    Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
    Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
    Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
    Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
    J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation.
    Cox N; Kintzing JR; Smith M; Grant GA; Cochran JR
    Angew Chem Int Ed Engl; 2016 Aug; 55(34):9894-7. PubMed ID: 27304709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
    Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
    Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
    Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.